Drug Manufacturers - Specialty & Generic
Companies engaged in development and discovery of branded forms of drug, drug-related products, generic drug products, and animal-related drugs. Also includes companies that cultivate, process, and farm cannabis or marijuana.
Market Cap
173.577B
Industry Weight
2.93%
Companies
85
Employees
128,679
Drug Manufacturers - Specialty & Generic S&P 500 ^GSPC
Loading Chart for Drug Manufacturers - Specialty & Generic

Day Return

Industry
4.82%
S&P 500
0.41%

YTD Return

Industry
2.48%
S&P 500
0.17%

1-Year Return

Industry
6.37%
S&P 500
12.77%

3-Year Return

Industry
7.46%
S&P 500
47.05%

5-Year Return

Industry
12.31%
S&P 500
100.31%

Note: Industry performance is calculated based on the previous closing price of all industry constituents

Largest Companies in This Industry

View More
Table View
Heatmap View
Name
Last Price
1Y Target Est.
Market Weight
Market Cap
Day Change %
YTD Return
Avg. Analyst Rating
160.35 194.43 40.08% 72.344B +3.51% -1.58%
Buy
131.87 132.00 7.74% 13.98B 0.00% +57.89%
Hold
303.92 388.18 7.52% 13.568B +1.41% -13.86%
Buy
120.27 159.40 6.75% 12.177B +1.25% -11.89%
Buy
8.79 11.75 5.81% 10.492B +4.39% -29.40%
Hold
12.94 14.18 3.54% 6.397B +0.47% +6.85%
Buy
79.78 129.31 3.07% 5.547B +1.23% -10.82%
Strong Buy
402.00 - 2.90% 5.231B +17.20% +8,037.65%
31.21 39.57 2.80% 5.05B +1.93% +8.52%
Buy
87.11 88.50 2.38% 4.304B +2.00% +11.55%
Buy

Investing in the Drug Manufacturers - Specialty & Generic Industry

Start Investing in Drug Manufacturers - Specialty & Generic Through These Companies

Top Performing Companies

View More
Name
Last Price
1Y Target Est.
YTD Return
402.00 - +8,037.65%
5.24 - +121.10%
7.10 9.75 +81.59%
131.87 132.00 +57.89%
19.70 29.00 +47.90%

High Growth Companies

View More
Name
Last Price
Growth Estimate
YTD Return
7.10 +457.14% +81.59%
29.34 +373.64% +2.41%
19.70 +325.00% +47.90%
31.21 +85.42% +8.52%
120.27 +62.35% -11.89%

Drug Manufacturers - Specialty & Generic Research

View More

Discover the Latest Analyst and Technical Research for This Industry

  • Analyst Report: Evotec SE

    Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

    Rating
    Price Target
     
  • Analyst Report: Prestige Consumer Healthcare Inc.

    Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige’s key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer’s Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.

    Rating
    Price Target
     
  • Daily – Vickers Top Buyers & Sellers for 05/15/2025

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

     
  • PBH: Raising target price to $91.00

    PRESTIGE CONSUMER HEALTHCARE has an Investment Rating of HOLD; a target price of $91.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.

    Rating
    Price Target
     

From the Community

Drug Manufacturers - Specialty & Generic News